SILVER SPRING, MD — The head of the FDA’s vaccine division has departed the agency for the second time, ending a tenure that lasted long enough to be controversial and not quite long enough to resolve any of the controversies it generated — a career arc that FDA historians, a group that is having an unusually eventful professional period, are calling “the first documented case of someone leaving the same job twice in under two years” and that career FDA staff are calling, more simply, “again.”
Dr. Vinay Prasad’s departure — described by the agency as something that happened and by Dr. Prasad, whose social media presence has been consistently larger than his regulatory profile, as something he will be discussing at length in his newsletter, his podcast, his Substack, and at least two forthcoming speaking engagements — follows a pattern that observers note is consistent: he arrives, reviews vaccine approval processes, makes decisions that generate significant scientific and regulatory debate, generates significant press coverage of the debate, and then departs in a manner characterized by the word “abrupt.”
This is the second departure. It is abrupt in the same way the first departure was abrupt. The FDA building has the same doors it had the first time. The exit was taken.
What Dr. Prasad Did
During his tenure at the FDA, Dr. Prasad made a series of decisions involving vaccine approvals and specialty drug reviews that split the scientific community roughly into camps that can be characterized as “this is a needed corrective to regulatory overreach” and “this is going to get people hurt,” with significant representation in both camps from people with genuine credentials who are genuinely not performing for cameras.
The specific decisions — involving COVID booster reviews, pediatric vaccine schedules, and several specialty drug approvals — are matters of active scientific and regulatory debate that Supposedly News, as a satirical publication, will not adjudicate, except to note that when FDA career staff describe a vaccine chief’s departure as both predictable and consequential, that observation deserves to be in the story.
Several FDA career scientists, reached by phone and uniformly requesting anonymity because they still work there and would like to continue doing so, used the word “uncertainty” to describe the regulatory environment following the departure. Two used the word “concern.” One used a word we cannot print in a family-adjacent satirical publication and then laughed in a way that suggested they had been holding it in.
The Bigger Picture, Which Is A Little Blurry Right Now
The FDA vaccine division chief’s departure is one of a series of senior public health official departures, reassignments, and structural changes at federal health agencies over the past fourteen months that, taken individually, each have explanations, and taken together, form a pattern that public health researchers describe as “a moment of significant institutional transition” and that practicing physicians describe as “we don’t know who to call.”
The CDC’s measles specialists are largely gone. The USPSTF — the independent panel that recommends preventive care standards — has not met in over a year. The NIH has had leadership turbulence. The FDA has now had two abrupt departures from the same vaccine leadership position.
“The institutions exist,” said Dr. Margaret Chin, a former CDC epidemiologist now at Johns Hopkins. “The buildings are there. The databases are there. The accumulated knowledge is mostly there, though some of it left with the people. What’s less clear is the decision-making continuity. Who is making which call, based on what criteria, and who knows how the last call was made.”
She was asked if this was a crisis.
“It is a situation,” she said carefully. “A situation that warrants attention. A situation in which the word ‘crisis’ is accurate in some framings and premature in others, and the difference between those framings is time, and we don’t know yet how much time we have.”
The Position
The FDA’s vaccine division chief position is now open for the second time in two years. The agency is expected to announce an interim appointment shortly. The interim appointment will make decisions about vaccine approvals while the permanent appointment process occurs, which takes time, during which the interim appointee will continue making decisions, which is how government works and which, public health officials note, is a process that functions better when it is not interrupted by recurring abrupt departures from a single critical position.
Dr. Prasad’s newsletter, as of Friday afternoon, has not yet addressed the departure. His podcast episode count is 847. His Substack subscriber count is not public. His exit from the FDA is currently public, confirmed, and, career observers note, the second one.
Yolanda Tippington, Science Correspondent, notes that she has covered federal health agency leadership changes for six years and that this particular story has tested her commitment to measured scientific communication in ways she did not anticipate when she chose this beat.